Grassley To Hold Hearing On EpiPen Settlement, CMS Authority To Prevent Misclassification

Senate Judiciary Chair Charles Grassley (R-IA) plans to hold a hearing after the November elections to examine the reported settlement between the Justice Department and EpiPen manufacturer Mylan and CMS' authority to hold companies accountable for misclassifying their products. “Mylan’s management of the EpiPen has not only led to higher costs for patients and their families, but also for taxpayers in Iowa and across the nation by misclassifying its product to dodge higher Medicaid rebate requirements. Americans deserve to know...